Business / Finance

RSS

Evolution Benefits and Lighthouse1 merge to create Evolution1

Evolution Benefits and Lighthouse1 announced today that they have completed merging their companies to create Evolution1. Evolution1 offers the nation's most comprehensive electronic payment, on-premise and cloud computing solutions for the administration of flexible spending accounts (FSAs), health savings accounts (HSAs), health reimbursement accounts (HRAs), VEBAs, wellness and transit plans.

11 Jul 2011

Anavex exercises warrants to raise $1.575 million

Anavex Life Sciences Corp. is pleased to announce that it has raised $1,575,000 through the exercise of warrants. Funds will be used to continue the Phase I clinical trial of ANAVEX 2-73, the company's lead drug candidate for Alzheimer's disease, to advance other compounds in the Anavex pipeline, and for general corporate purposes.

11 Jul 2011

Generex announces convertible preferred stock securities purchase agreement

Generex Biotechnology Corporation today announced that it entered into a securities purchase agreement with certain institutional investors on July 8, 2011.

11 Jul 2011

Sanofi announces strategic divestiture of dermatology business to Valeant

Sanofi announced today the strategic divestiture of its dermatology business, Dermik, to Valeant Pharmaceuticals International Inc., for a total cash consideration of US $425 million. Valeant is a pharmaceutical company focused on the neurology and dermatology therapeutic areas, based in Mississauga, Ontario, Canada.

11 Jul 2011

USANA receives FDA registration to manufacture OTC drugs

USANA Health Sciences, Inc. today announced it has obtained the U.S. Food and Drug Administration's "Drug Establishment Registration," allowing the company to manufacture over-the-counter (OTC) drugs and holding it to a standard well above what is required of a dietary supplement manufacturer.

11 Jul 2011

Illumina, Sequenom sign three-year supply agreement

Sequenom, Inc., a life sciences company providing innovative genetic analysis solutions, today announced it has signed a three-year supply agreement with Illumina, Inc., a leading developer and manufacturer of life sciences tools for the large-scale analysis of genetic variation and function.

From Illumina, Inc. 11 Jul 2011

ITT enters definitive agreement to acquire YSI

ITT Corporation and privately held YSI Incorporated today announced a definitive agreement for ITT to acquire, via merger, YSI, a leading developer and manufacturer of sensors, instruments, software, and data collection platforms for environmental water monitoring.

11 Jul 2011

CCBC repurchases an aggregate of 2,052,607 ordinary shares

China Cord Blood Corporation, the first and largest cord blood banking operator in China, today announced that the Company repurchased an aggregate of 2,052,607 ordinary shares.

11 Jul 2011

Getinge net sales decline 8.4% to SEK 9,634 M for second quarter 2011

Getinge AB: Reporting period January - June. Orders received declined by 7.2% to SEK 10,395 M (11,204) but increased organically by 2.2%

11 Jul 2011

Isogenica opens new automation facility

Isogenica Ltd today announced the opening of a new automation facility at their current location, Chesterford Research Park.

11 Jul 2011

Valeant signs agreement to acquire Dermik

Valeant Pharmaceuticals International, Inc. announced today that Valeant and its subsidiary, Valeant International SRL, have signed an agreement to acquire Dermik, a dermatology unit of Sanofi in the U.S. and Canada, as well as the worldwide rights to Sculptra Aesthetic.

11 Jul 2011

QIAGEN to acquire Cellestis

QIAGEN N.V. today announced that it has amended its original proposal to acquire Cellestis Limited, a publicly traded Australian biotechnology company.

From QIAGEN Manchester Limited 11 Jul 2011

Study finds higher rate of switching from Byetta to Victoza in treatment of type 2 diabetes

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that although Amylin/Eli Lilly's Byetta currently commands a higher patient share than Novo Nordisk's Victoza, more patients were switched from Byetta to Victoza than vice versa (25.2 percent versus 2.8 percent) in the last quarter of 2010 among recently treated type 2 diabetes patients.

8 Jul 2011

Allegro completes $5.4M Series A extension financing

Allegro Diagnostics today announced that it has closed a $5.4M Series A extension financing. The company's existing venture investors, Kodiak Venture Partners and Catalyst Health Ventures, participated in the round.

8 Jul 2011

Medtronic enters definitive agreement to acquire Salient Surgical Technologies

Medtronic, Inc. today announced that it has entered into a definitive agreement to acquire Salient Surgical Technologies, Inc., the leader in the advanced energy category for haemostatic sealing of soft tissue and bone in a variety of surgical procedures including orthopaedic surgery, spine, open abdominal and thoracic procedures.

From Medtronic 8 Jul 2011

Medtronic enters definitive agreement to acquire PEAK Surgical

Medtronic, Inc. today announced that it has entered into a definitive agreement to acquire PEAK Surgical, Inc., a recognized leader in the emerging field of advanced energy surgical incision technology to broaden Medtronic Surgical Technologies' portfolio of innovative surgical products to meet customer and patient needs worldwide.

From Medtronic 8 Jul 2011

Managed care enters the exam room as insurers buy doctor groups

Kaiser Health News staff writer Christopher Weaver, working in collaboration with The Washington Post, reports: "Even if UnitedHealth Group isn't your insurance company, there's a good chance it touches you in some way.

6 Jul 2011

Erratic investment responses can make a smart portfolio richer

Playing the stock market can be a risky game. And when the market behaves unpredictably, public fear can lead to erratic investment responses and market chaos.

1 Jul 2011

Premature ejaculation treatment market to reach over $1.3 billion by 2017

In 2010 the premature ejaculation treatment market was estimated to be worth $684 million, according to a new research report available on companiesandmarkets.com.

30 Jun 2011

Lotus Tissue Repair to develop DEB protein replacement therapy with $26 million Series A financing

Lotus Tissue Repair, Inc. today announced the closing of a $26 million Series A financing led by Third Rock Ventures. Proceeds of the financing will be used to advance the company's proprietary recombinant collagen type VII (rC7) technology as the first and only protein replacement therapy in development for the treatment of dystrophic epidermolysis bullosa (DEB), an orphan disease that causes devastating skin blisters, morbidity and early mortality.

30 Jun 2011